In the DASH (Dietary Approaches to Stop Hypertension) trials, a diet rich in fruits, vegetables, nuts and dairy products, and limited in fat content, was shown to be useful in controlling hypertension, particularly in African Americans (AA). Key components of such a diet are potassium, magnesium, and alkali, each of which has been implicated in lowering blood pressure. In the original IND 116,208, the investigators explored whether potassium-magnesium citrate (KMgCit) as a powder pharmaceutical formulation (dissolved in water before ingestion) could serve as a surrogate for the DASH diet and would lower blood pressure among patients with pre- or Stage I hypertension. Unfortunately, previous studies did not include adequate number of African American patients.

Start Date15 Dec 2024

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

NCT04651088 / Not yet recruitingEarly Phase 1IIT

Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet

The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

NCT05918029 / RecruitingPhase 2/3IIT

Bone in CKD Alkali Response Pilot Trial (BICARb)

The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are:
To evaluate effects of potassium citrate treatment on bone quality and strength.
To evaluate mechanism(s) underlying the effects of potassium citrate on skeletal health.
Participants will be asked to:
provide blood, urine and answer questions about health and diet three times during an 8 months period
undergo advanced bone imaging with high resolution-peripheral quantitative CT scan twice during 8 months
take study pills for 4-6 weeks at the beginning of the study to ensure safety
take either potassium citrate or placebo for 6 months during the blinded portion of the study
Researchers will compare the bone imaging between the potassium citrate and the placebo groups at the end of the study.

Start Date01 Jun 2024

Sponsor / Collaborator

Albert Einstein College of Medicine, Inc.

[+4]

100 Clinical Results associated with Potassium Citrate

100 Translational Medicine associated with Potassium Citrate

100 Patents (Medical) associated with Potassium Citrate

663

Literatures (Medical) associated with Potassium Citrate

01 Feb 2024·The Journal of urology

Alkaline Water: Help or Hype for Uric Acid and Cystine Urolithiasis?

Article

Author: McCormac, Amanda ; Clayman, Ralph V ; Asplin, John ; Vu, Minh-Chau ; Cumpanas, Andrei D ; Bhatt, Rohit ; Tano, Zachary E ; Piedras, Paul ; Rojhani, Allen ; Lavasani, Seyed Amiryaghoub M ; Gorgen, Antonio R H ; Landman, Jaime ; Patel, Roshan M

PURPOSE:

The consumption of alkaline water, water with an average pH of 8 to 10, has been steadily increasing globally as proponents claim it to be a healthier alternative to regular water. Urinary alkalinization therapy is frequently prescribed in patients with uric acid and cystine urolithiasis, and as such we analyzed commercially available alkaline waters to assess their potential to increase urinary pH.

MATERIALS AND METHODS:

Five commercially available alkaline water brands (Essentia, Smart Water Alkaline, Great Value Hydrate Alkaline Water, Body Armor SportWater, and Perfect Hydration) underwent anion chromatography and direct chemical measurements to determine the mineral contents of each product. The alkaline content of each bottle of water was then compared to that of potassium citrate (the gold standard for urinary alkalinization) as well as to other beverages and supplements used to augment urinary citrate and/or the urine pH.

RESULTS:

The pH levels of the bottled alkaline water ranged from 9.69 to 10.15. Electrolyte content was minimal, and the physiologic alkali content was below 1 mEq/L for all brands of alkaline water. The alkali content of alkaline water is minimal when compared to common stone treatment alternatives such as potassium citrate. In addition, several organic beverages, synthetic beverages, and other supplements contain more alkali content than alkaline water, and can achieve the AUA and European Association of Urology alkali recommendation of 30 to 60 mEq per day with ≤ 3 servings/d.

CONCLUSIONS:

Commercially available alkaline water has negligible alkali content and thus provides no added benefit over tap water for patients with uric acid and cystine urolithiasis.

01 Dec 2023·Hypertension (Dallas, Tex. : 1979)

Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone

Article

Author: Wang, Jijia ; Murillo, Ashley ; Johnson, Talon ; Giacona, John M ; Ren, Jimin ; Pak, Charles C Y ; Moe, Orson W ; Vongpatanasin, Wanpen ; Khan, Ghazi ; Pittman, Danielle

BACKGROUND::

Thiazide diuretics (TD) are the first-line treatment of hypertension because of its consistent benefit in lowering blood pressure and cardiovascular risk. TD is also known to cause an excess risk of diabetes, which may limit long-term use. Although potassium (K) depletion was thought to be the main mechanism of TD-induced hyperglycemia, TD also triggers magnesium (Mg) depletion. However, the role of Mg supplementation in modulating metabolic side effects of TD has not been investigated. Therefore, we aim to determine the effect of potassium magnesium citrate (KMgCit) on fasting plasma glucose and liver fat by magnetic resonance imaging during TD therapy.

METHODS::

Accordingly, we conducted a double-blinded RCT in 60 nondiabetic hypertension patients to compare the effects of KCl versus KMgCit during chlorthalidone treatment. Each patient received chlorthalidone alone for 3 weeks before randomization. Primary end point was the change in fasting plasma glucose after 16 weeks of KCl or KMgCit supplementation from chlorthalidone alone.

RESULTS::

The mean age of subjects was 59±11 years (30% Black participants). Chlorthalidone alone induced a significant rise in fasting plasma glucose, and a significant fall in serum K, serum Mg, and 24-hour urinary citrate excretion (all P <0.05). KMgCit attenuated the rise in fasting plasma glucose by 7.9 mg/dL versus KCl ( P <0.05), which was not observed with KCl. There were no significant differences in liver fat between the 2 groups.

CONCLUSIONS::

KMgCit is superior to KCl, the common form of K supplement used in clinical practice, in preventing TD-induced hyperglycemia. This action may improve tolerability and cardiovascular safety in patients with hypertension treated with this drug class.

01 Nov 2023·Veterinary medicine and science

Effects of two commercial diets and two supplements on urinary pH in dogs

Article

Author: Vernooij, Johannes C M ; Igreja, Inês Alcaide ; Lourenço, Ana Luísa ; Corbee, Ronald Jan

Abstract:

Background:

Urinary pH manipulation by therapeutic foods or supplements is part of the treatment for urolithiasis. The effectiveness of these diets and supplements should be studied to determine which of these strategies is most effective.

Hypothesis/Objectives:

To assess the effect of the oral supplementation of potassium citrate, an ammonium chloride solution (Urical) and two dry therapeutic foods—Hill's® Prescription Diet® u/d® Canine (u/d diet) and Royal Canin® Urinary S/O dog (S/O diet)—on a dog's urinary pH at different time points over 8 h.

Animals:

Seven healthy adult male research beagle dogs.

Methods:

A prospective interventional study lasting 31 days. The dogs either received a supplement (potassium citrate or rical) with a dry adult maintenance diet (control diet) or the therapeutic diet (u/d diet or S/O diet). Each treatment had a duration of 2–5 days, with 2‐ to 4‐day washout periods in between. Urinary pH measurements were performed every 2 h between 07h00 and 15h00, with the food being given at 07h00 and 15h00, right after urine collection. The pH measurements obtained in each of the four treatments were compared to control (same dogs fed the control diet exclusively).

Results:

When compared to the control diet at the same time points, biologically relevant changes in urinary pH (defined as ≥0.5) were: increase with potassium citrate at 7h00 and 13h00; increase with u/d diet at 9h00, 13h00, and 15h00; decrease with S/O diet at 9h00 and 11h00; Urical did not have a detectable effect on urinary pH.

Conclusions and Clinical Importance:

The present study confirms that therapeutic foods S/O and u/d, and potassium citrate supplement affected acid‐base balance in healthy adult male beagle dogs, with the tested diets being more effective than the administered doses of the tested supplements at influencing urinary pH.

News (Medical) associated with Potassium Citrate

17 Jan 2024

·www.drugs.com

Commercially Available Alkaline Water Not Likely to Prevent Kidney Stones

WEDNESDAY, Jan. 17, 2024 -- Commercially available alkaline water is not likely to provide benefit over tap water for patients with uric acid and cystine urolithiasis, according to a study published in the February issue of The Journal of Urology . Paul Piedras, from the University of California at Irvine, and colleagues analyzed five commercially available alkaline waters to assess their potential to increase urinary pH compared to potassium citrate, the gold standard for urinary alkalinization. The researchers found that the pH levels of the bottled alkaline water ranged from 9.69 to 10.15. For all brands, electrolyte content was minimal and the physiologic alkali content was below 1 mEq/L. Compared with potassium citrate, the alkali content of alkaline water is minimal. Other organic beverages, synthetic beverages, and supplements contain more alkali content than alkaline water and can achieve the American Urological Association and European Association of Urology alkali recommendation of 30 to 60 mEq per day with no more than three servings per day. "Commercially available alkaline water has negligible alkali content and thus provides no added benefit over tap water for patients with uric acid and cystine urolithiasis," the authors write. One author disclosed employment with Litholink, a subsidiary of LabCorp. Abstract/Full Text Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

15 Jan 2024

·www.drugs.com

High-Alkaline Water Won't Prevent Kidney Stones

MONDAY, Jan. 15, 2024 -- Trendy bottled water marketed as “alkaline water” isn’t likely to prevent kidney stones in a person plagued by them, a new study reports. These products tend to have contain less alkali than is needed to alter urine pH level enough to keep stones from forming, said senior study author Dr. Roshan Patel , a urologist with the University of California, Irvine. "While alkaline water products have a higher pH than regular water, they have a negligible alkali content – which suggests that they can't raise urine pH enough to affect the development of kidney and other urinary stones," Patel said in a university news release. Alkaline water, also called high pH water, has become increasingly popular, researchers said in background notes. Tap water has a typical pH around 7.5, while alkaline water has a pH in the range of 8 to 10, the researchers said. Raising pH is a key strategy to prevent kidney stones in patients who’ve previously had stones, researchers said. This is typically done through potassium citrate tablets prescribed to patients. But many patients aren’t fond of taking the large pills several times a day, and alkaline water offers an attractive alternative, researchers said. To see whether high pH water could help, Patel and his colleagues tested five alkaline water products that are on the market. They also reviewed published data on other types of drinks and over-the-counter products that might increase urinary pH. The five bottled alkaline waters all had similar pH levels, around 10. But at a pH of 10, the tested products would still have an alkali content of just 0.1 milliequivalent per liter (mEq/L). That's a "trivial" concentration compared to the body's typical metabolic acid production of 40 to 100 mEq/L per day, Patel says. By contrast, other products available for purchase do have the potential to increase pH. For example, plain old orange juice – with an alkali content of up to 15 mEq/L – provides the most cost-effective means of reaching a target alkali concentration of 30 mEq per day, researchers said. Another effective, low-cost option is baking soda, although researchers said there are concerns about the sodium in the soda. "Our findings may help to guide the selection of other treatments, including beverages and over-the-counter products, for preventing recurrent urinary stones," Patel said. The researchers noted that these are lab studies of products, and that clinical trials need to be performed to best test options for increasing urinary pH. The new study was published in the Journal of Urology . Sources American Urological Association, news release, Jan. 10, 2024 Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

04 Oct 2023

·www.prnewswire.com

UCB presents late-breaking posters at Child Neurology Society Meeting

ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of this conference, UCB will present two late-breaking posters that shed light on the care and management of Dravet syndrome. Poster 1: Outcomes Among Individuals With Dravet Syndrome Using Fenfluramine: A Retrospective Analysis Using U.S. Claims Data Continue Reading Fintepla® (fenfluramine) 2.2 mg/mL oral solution) Dravet syndrome, a rare and severe developmental epileptic encephalopathy, has long presented challenges in terms of treatment and care. However, a new retrospective analysis utilizing U.S. claims data has unveiled promising outcomes for individuals with Dravet syndrome who were treated with fenfluramine, following its approval in June 2020 for the management of seizures associated with Dravet syndrome in the United States.1 The objective of this analysis was to quantify the relationship between fenfluramine and seizure-related healthcare events through claims data. The study utilized the Komodo U.S. healthcare claims database to measure healthcare utilization, including rescue anti-seizure medication use and healthcare visits. Individuals with Dravet syndrome were identified by ICD-10 codes. Patients receiving prior/concomitant cannabidiol or stiripentol were excluded.1 Among the 108 individuals with Dravet syndrome included in the analysis, 91 individuals (84%) had continuous fenfluramine use for a minimum of 6 months. This subset exhibited a 77% reduction in rescue antiseizure medication use (P<0.001). Moreover, the reductions extended to healthcare visits, with a 50% decrease in ER visits, a 27% reduction in outpatient visits, a 24% reduction in neurology visits, and a 24% reduction in inpatient hospitalizations.1 The findings suggest that meaningful reductions in healthcare utilization were observed among individuals with Dravet syndrome treated with fenfluramine for at least 6 months. The 6-month persistency rate of fenfluramine usage indicates not only its efficacy but also its tolerability in this patient population.1 Authors: Srihari Jaganathan, Derek Ems, Rob Sederman, Chen Chen, Shuang Wu Poster 2: Diagnosis and Information Management of Dravet Syndrome in Recently Diagnosed Pediatric Patients: Results From a Dravet Syndrome Foundation Caregiver Insight Survey The second late-breaking poster explored the challenges surrounding the early diagnosis of Dravet syndrome. Caregivers of pediatric patients aged ≤4 years, diagnosed with Dravet syndrome, were surveyed to gather insights into their experiences.2 The survey, distributed via the Dravet Syndrome Foundation Family Network, received responses from 73 caregivers. The results highlighted that the average age at symptom onset was 5 months, while the average age at Dravet syndrome diagnosis was 12 months. Changes in healthcare providers were common, with the most frequent reasons being clinical expertise and trust. The poster further highlights the vital role that patient advocacy groups and online resources play in providing caregivers with valuable information and support during the diagnosis and management process.2 Authors: Andrea Wilkinson, BA, Danya Kaye, BA, Veronica Hood, PhD, Mary Anne Meskis, Laurie Bailey, BCPA, Rebecca Burns, PharmD, PhD, Amélie Lothe, PhD These posters underscore the advancements in understanding and managing Dravet syndrome, as well as the pivotal role of both medical interventions and patient advocacy resources in enhancing the lives of those affected by this condition.1,2 About FINTEPLA® (fenfluramine)1 In the U.S., FINTEPLA is approved for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. FINTEPLA is available in the U.S. through the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS). Further information is available at or by telephone at 1-877-964-3649. Please see full Prescribing Information, including Boxed Warning, for additional important information on FINTEPLA. INDICATION FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older. It is not known if FINTEPLA is safe and effective in children less than 2 years of age. IMPORTANT SAFETY INFORMATION FINTEPLA can cause serious side effects, including: 1. Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension) have been associated with fenfluramine, the active ingredient in FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and to evaluate for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA. Call your healthcare provider right away if you develop any of these signs and symptoms of heart or lung problems during treatment with FINTEPLA: shortness of breath chest pain tiredness or weakness, especially with increased activity sensations of a rapid, fluttering heartbeat (palpitations) lightheadedness or fainting irregular pulse swollen ankles or feet bluish color of your lips and skin (cyanosis) Because of the risk of heart valve problems (valvular heart disease) and high blood pressure in arteries of lungs (pulmonary arterial hypertension), FINTEPLA is only available through a restricted program called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS). Before you or your child receives FINTEPLA, your healthcare provider or pharmacist will make sure you understand how to take FINTEPLA safely. If you have any questions about FINTEPLA, ask your healthcare provider, visit , or call 1-877-964-3649. 2. Decreased appetite and decreased weight. Decreased appetite and decreased weight are both serious and common side effects of FINTEPLA in people with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS). Your weight should be checked regularly during your treatment with FINTEPLA. Your healthcare provider may need to make changes to your FINTEPLA dose if your weight decreases. In some cases, FINTEPLA may need to be stopped. 3. Sleepiness, sedation, and lack of energy (lethargy). These are both serious and common side effects of FINTEPLA in people with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS). Taking FINTEPLA with central nervous system (CNS) depressants, including alcohol, may increase sleepiness. Do not drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you. 4. Like all other antiepileptic drugs, FINTEPLA may cause suicidal thoughts or actions in a very small number of people (about 1 in 500). Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying new or worse anxiety trouble sleeping (insomnia) acting on dangerous impulses attempts to commit suicide feeling agitated or restless other unusual changes in behavior or mood new or worse irritability an extreme increase in activity and talking (mania) new or worse depression panic attacks acting aggressive, being angry or violent How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 5. Do not stop taking FINTEPLA without first talking to your healthcare provider. Stopping a seizure medicine such as FINTEPLA can suddenly cause you to have seizures more often or seizures that do not stop (status epilepticus).Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not take FINTEPLA if you: are allergic to fenfluramine or any of the ingredients in FINTEPLA. See below for a complete list of ingredients in FINTEPLA. are taking or have stopped taking medicines called monoamine oxidase inhibitors (MAOIs) in the last 14 days. This may cause a serious or life-threatening problem called serotonin syndrome. If you are not sure whether or not you are taking one of these medicines, contact your healthcare provider. Before taking FINTEPLA, tell your healthcare provider about all of your medical conditions, including if you: have heart problems have or have had weight loss have or have had depression, mood problems, or suicidal thoughts or behavior have kidney problems have liver problems are pregnant or plan to become pregnant. Tell your healthcare provider right away if you become pregnant while taking FINTEPLA. You and your healthcare provider will decide if you should take FINTEPLA while you are pregnant. If you become pregnant while taking FINTEPLA, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334 or go to . The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. are breastfeeding or plan to breastfeed. It is not known if FINTEPLA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking FINTEPLA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. How should I take FINTEPLA? Read the Instructions for Use for information on the right way to use FINTEPLA. Take FINTEPLA exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you how much FINTEPLA to take and when to take it. FINTEPLA may be taken with or without food. Measure your dose of FINTEPLA using the dosing syringe that is provided by the pharmacy. Do not use a household teaspoon or tablespoon. FINTEPLA can be given through gastric and nasogastric feeding tubes. What should I avoid while taking FINTEPLA? Do not drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you. FINTEPLA may cause you to feel sleepy. What are the possible side effects of FINTEPLA? FINTEPLA may cause serious side effects, including: See " FINTEPLA can cause serious side effects" above Serotonin syndrome. Serotonin syndrome is a life-threatening problem that can happen in people taking FINTEPLA, especially if FINTEPLA is taken with certain other medicines including: anti-depressant medicines called SSRIs, SNRIs, TCAs, and MAOIs; tryptophan; lithium; antipsychotics; St. John's Wort; dextromethorphan; tramadol. Call your healthcare provider right away if you have any of the following symptoms of serotonin syndrome: mental status changes such as seeing things that are not there (hallucinations), agitation, or coma changes in blood pressure tight muscles fast heartbeat nausea, vomiting, diarrhea high body temperature trouble walking High blood pressure (hypertension). Hypertension is both a serious and common side effect. FINTEPLA can cause your blood pressure to increase even if you have never had high blood pressure before. Your healthcare provider will check your blood pressure while you are taking FINTEPLA. Increased pressure in your eyes (glaucoma). Symptoms of glaucoma may include: red eyes seeing halos or bright colors around lights nausea or vomiting decreased vision eye pain or discomfort blurred vision If you have any of these symptoms, call your healthcare provider right away. The most common side effects of FINTEPLA when used to treat Dravet syndrome (DS) include: decreased appetite diarrhea low energy respiratory infection decreased weight fever constipation abnormal echocardiogram sleepiness problems with movement, balance, and walking increased drooling increased blood pressure vomiting falls seizures that do not stop weakness The most common side effects of FINTEPLA when used to treat Lennox-Gastaut syndrome (LGS) include : diarrhea tiredness vomiting sleepiness decreased appetite These are not all the possible side effects of FINTEPLA. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1–800–FDA–1088. Keep FINTEPLA and all medicines out of the reach of children. General information about the safe and effective use of FINTEPLA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FINTEPLA for a condition for which it was not prescribed. Do not give FINTEPLA to other people, even if they have the same symptoms that you have. It may harm them. What are the ingredients in FINTEPLA? Active ingredient: fenfluramine hydrochloride Inactive ingredients: cherry flavor, citric acid, ethylparaben, hydroxyethylcellulose, methylparaben, potassium citrate, sucralose, and water. FINTEPLA contains no ingredient made from gluten-containing grain (wheat, barley, or rye) and contains not more than 0.1% of carbohydrates, which is from the cherry flavoring. Please see full Prescribing Information, including Medication Guide, for additional Important Safety Information on FINTEPLA. For further information, contact UCB: Corporate Communications Becky Malone, U.S. Media Relations T +919.605.9600 [email protected] Investor Relations Antje Witte T +32.2.559.9414 [email protected] About UCB UCB, Brussels, Belgium () is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,600 people in approximately 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA. References _______________________________________ 1. Srihari Jaganathan, Derek Ems, Rob Sederman, Chen Chen, Shuang Wu; Outcomes Among Individuals with Dravet Syndrome Using Fenfluramine: A Retrospective Analysis Using U.S. Claims Data 2. Andrea Wilkinson, BA, Danya Kaye, BA, Veronica Hood, Ph.D., Mary Anne Meskis, Laurie Bailey, BCPA, Rebecca Burns, PharmD, Ph.D., Amélie Lothe, Ph.D.; Diagnosis and Information Management of Dravet Syndrome in Recently Diagnosed Pediatric Patients: Results from a Dravet Syndrome Foundation Caregiver Insight Survey FINTEPLA® is a registered trademark of the UCB Group of Companies. ©2023 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-P-FA-DS-2300472 SOURCE UCB

Drug ApprovalClinical ResultClinical Study

100 Deals associated with Potassium Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D05578	Potassium Citrate	A12BA02	DB09125

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypokalemia	CN	Hunan Huari Pharmaceutical Co Ltd	01 Jan 1994
Acidosis, Renal Tubular	US	Mission Pharmacal Co.	30 Aug 1985
Nephrolithiasis, Calcium Oxalate	US	Mission Pharmacal Co.	30 Aug 1985
Uric acid renal calculus	US	Mission Pharmacal Co.	30 Aug 1985
Urogenital Diseases	AU	Lacuna Pharma Pty Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MP26-11 (AUA2024)	Not Applicable	urinary potassium	854	Potassium citrate tablets	yzrqtzngfm(hwnedjesuf) = hmpodyruiq yjyyyqupth (dqwnzbklbg )	Positive	01 May 2024
NCT02665117 (CTgov)	Not Applicable	Hypertension	61	KMgCit+Potassium Magnesium Citrate (KMgCit)+chlorthalidone (KMgCit + Chlorthalidone)	qlucogbagg(zqntrhadks) = xmnpppyesl tozkniaijr (lylpkkyjjv, wbhxxbsdbi - ltjrkiursk) View more	-	25 Oct 2023
				Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone)	qlucogbagg(zqntrhadks) = sicscwbkwg tozkniaijr (lylpkkyjjv, loftpptcax - vywvkdgmmk) View more
MP31-05 (AUA2018)	Not Applicable	Uric acid renal calculus	161	potassium citrate (Patients with DM)	erazqfrwwa(ylbamliuel) = nmcbzbxkax zxhoxdmtbp (vfqbahkoyo ) View more	-	01 Apr 2018
				potassium citrate (Patients without DM)	erazqfrwwa(ylbamliuel) = scgbiwtqgf zxhoxdmtbp (vfqbahkoyo ) View more
ASN2017	Not Applicable	-	111	KCl	flmpwnegkl(mceuymsgre) = xmacenldri njacjaisfg (omipfddbuk, 0.6) View more	Positive	31 Oct 2017
				KCit+CTD	flmpwnegkl(mceuymsgre) = mesaajrpux njacjaisfg (omipfddbuk, 0.3) View more
NCT00357331 (CTgov)	Phase 4	Osteoporosis, Postmenopausal	83	potassium citrate (Placebo)	pylcllbalu(yqpohndzgp) = gtdkwveajr pyzrykumzy (cvjhvuvkmd, mkkuaflloj - rtkpjmjmzo) View more	-	12 Jun 2017
				potassium citrate (Potassium Citrate)	pylcllbalu(yqpohndzgp) = athgiwcqar pyzrykumzy (cvjhvuvkmd, xouoxngmxx - jalilmimut) View more
NCT02349685 (CTgov)	Not Applicable	Helicobacter Infections	219	antimicrobial susceptibility test	tjktnjdtkn(pjfqubduqc) = cuhgpndwzh hnnewbrwye (nyohlmukzl, renpiscsau - vjsifbfmiy) View more	-	04 Oct 2016
NCT02653560 (CTgov)	Phase 4	Hypertension	30	Potassium magnesium Citrate (KMgCit) (Potassium Magnesium Citrate (KMgCit) Arm)	cnosttnqgc(kozqprirga) = hbfslljhbq xfeiephyzo (ygydpeapxt, ngigztivqo - fuakkejauq) View more	-	28 Jul 2016
				Potassium citrate powder (Potassium Citrate Arm)	cnosttnqgc(kozqprirga) = bbrbwbcqwn xfeiephyzo (ygydpeapxt, vpilxpkgzw - vlcfdltqtb) View more
ASN2014	Not Applicable	-	-	Potassium Citrate	lnkabnjrgm(prqvwtrqyy) = yiwmptadqt ivtqafaxgu (kkdvjbates, 0.5) View more	Negative	11 Nov 2014
				KCl	lnkabnjrgm(prqvwtrqyy) = yejfkeptnn ivtqafaxgu (kkdvjbates, 0.3) View more
MP27-09 (AUA2014)	Not Applicable	Obesity	-	potassium citrate (Obese patients)	kmruedlyeh(jcigvmckcp) = vkmirpzntv friviuytvl (fkmvpxzcrx )	-	01 Apr 2014
				potassium citrate (Non-obese patients)	xeormfnxrf(plmvtxikge) = mqfurcfrvy qtqhputgll (gopweiqxss ) View more
NCT00913796 (Pubmed \| Clin J Am Soc Nephrol)	Phase 2	Acidosis	30	Potassium citrate	ltctamknsy(iinyyffwki) = srucsgzpty gfnpsngsbf (gnahpnodpw )	-	01 Sep 2012
				Potassium chloride	ltctamknsy(iinyyffwki) = tcdafqkzin gfnpsngsbf (gnahpnodpw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis